
<table>
<thead>
<tr>
<th><strong>Opening date:</strong></th>
<th>15 March 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Minimum data due in</strong></td>
<td>17:00 AEST on 10 April 2019</td>
</tr>
<tr>
<td><strong>NHMRC’s granting system:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Closing date and time:</strong></td>
<td>17:00 AEST on 15 May 2019</td>
</tr>
<tr>
<td><strong>Commonwealth policy entity:</strong></td>
<td>Cancer Australia</td>
</tr>
<tr>
<td><strong>Enquiries:</strong></td>
<td>Applicants requiring further assistance should direct enquiries to their Administering Institution's Research Administration Officer. Research Administration Officers can contact Cancer Australia’s grants help centre for further advice: Contact Officer: Dr Christopher Poon, SPO Research Telephone: 03 8539 8085 Email: <a href="mailto:grants@canceraustralia.gov.au">grants@canceraustralia.gov.au</a> Cancer Australia will not respond to any enquiries submitted later than 2 business days before the closing date for application submission</td>
</tr>
<tr>
<td><strong>Date guidelines released:</strong></td>
<td>15 March 2019</td>
</tr>
<tr>
<td><strong>Type of grant opportunity:</strong></td>
<td>Targeted competitive</td>
</tr>
</tbody>
</table>
Contents


2. About the grant program .................................................................................................................. 5
  2.1 About the PdCCRS Project Grant opportunity ........................................................................... 14
    2.1.1 About the PdCCRS Standard Project Grant opportunity .............................................. 14
    2.1.2 About the PdCCRS Early Career Researcher Project Grant opportunity .................... 15

3. Grant amount and grant period ...................................................................................................... 15
  3.1 Grants available ............................................................................................................................. 15
  3.2 Grant period ................................................................................................................................ 16

4. Eligibility criteria ............................................................................................................................. 16
  4.1 Submission Deadlines .................................................................................................................. 17
  4.2 Chief Investigators and number of grant submissions ............................................................... 17
  4.3 Multiple applications/grants ........................................................................................................ 17
  4.4 Grant Category Specific Eligibility criteria ................................................................................ 18
    4.4.1 Standard Project Grants – Category A .............................................................................. 18
    4.4.2 Early Career Researcher Project Grants – Categories B, C and D ..................................... 18
    4.4.2.1 Eligibility for funding by Cure Cancer .......................................................................... 19
  4.5 Who is eligible to apply for a grant? ........................................................................................... 19
  4.6 Who is not eligible to apply for a grant? ..................................................................................... 20

5. What the grant money can be used for .......................................................................................... 20
  5.1 Eligible grant activities ............................................................................................................... 20
  5.2 Eligible locations ........................................................................................................................ 20
  5.3 Eligible expenditure .................................................................................................................... 20
  5.4 What the grant money cannot be used for ................................................................................ 21

6. The assessment criteria ................................................................................................................... 21
  6.1 Standard Project Grants Assessment Criteria ............................................................................ 21
  6.2 Early Career Researcher Project Grants Assessment Criteria .................................................. 23

7. How to apply ................................................................................................................................... 24
  7.1 Overview of application process and timing .............................................................................. 24
  7.2 PdCCRS Application requirements ........................................................................................... 25
  7.3 PdCCRS application submission ............................................................................................... 26
  7.4 Withdrawal of applications ........................................................................................................ 26
  7.5 Questions during the application process ................................................................................... 27

8. The grant selection process ............................................................................................................ 27
  8.1 Assessment of grant applications ............................................................................................... 27
  8.2 Who will assess applications? ..................................................................................................... 27
  8.3 Who will approve grants? ............................................................................................................. 28

9. Notification of application outcomes .............................................................................................. 28
10. Successful grant applications .............................................................. 28
  10.1 The grant agreement ................................................................. 28
  10.2 Information required from grant recipients .................................. 29
  10.3 Specific legislation, policies and industry standards ....................... 29
  10.4 How we pay the grant .................................................................. 29
  10.5 Grants Payments and GST ............................................................. 29
      10.5.1 Taxation ............................................................................ 29
      10.5.2 Goods and Services Tax (GST) ........................................... 30

11. Announcement of grants .................................................................. 30

12. How Cancer Australia monitors grant activity .................................. 30
  12.1 Variations .................................................................................. 30
  12.2 Reporting .................................................................................. 30
      12.2.1 Annual Financial Reports ..................................................... 31
      12.2.2 Annual Progress reports ....................................................... 31
      12.2.3 Ad-hoc reports ................................................................... 31
      12.2.4 Final report ........................................................................ 31
      12.2.5 Audited financial acquittal report ........................................ 32
  12.3 Compliance visits ...................................................................... 32
  12.4 Evaluation .................................................................................. 32
  12.5 Acknowledgement ..................................................................... 32

13. Probity ............................................................................................ 33
  13.1 Enquiries and feedback ............................................................... 33
  13.2 Conflicts of interest .................................................................... 33
  13.3 Privacy ....................................................................................... 34
  13.4 Confidential information ............................................................. 34
  13.5 Freedom of information ............................................................... 35

14. Cancer Australia policies ................................................................. 36

15. Glossary ........................................................................................... 36

16. Attachment A PdCCRS Grant Characteristics/Attributes ............... 39

17. Attachment B PdCCRS Assessment Process Map – Standard Project Grants (Category A) ................................................................. 40


**Cancer Australia’s PdCCRS is designed to achieve Australian Government objectives**

This grant opportunity is a component of the Portfolio Budget Statements (PBS) Program 1.1: Improved cancer control, which contributes to Outcome 1: Minimised impacts of cancer, including through national leadership in cancer control with targeted research and clinical trials; evidence informed clinical practice; strengthened national data capacity; community and consumer information and support. Cancer Australia works with stakeholders to plan and design the grant program according to the Commonwealth Grants Rules and Guidelines (CGRGs).

---

**The grant opportunity opens**

Cancer Australia publishes the grant guidelines and advertises on GrantConnect.

---

**PdCCRS applicants complete and submit joint grant applications**

Applicants are required to complete and submit a grant application to the National Health and Medical Research Council (NHMRC) Ideas Grants or Clinical Trials and Cohort Studies Grants schemes via the NHMRC granting system, indicating that the application is to be considered for funding by Cancer Australia. Applicants are also required to complete the relevant PdCCRS Questions application form for submission directly to Cancer Australia.

---

**PdCCRS Applications verified**

Applications to NHMRC and Cancer Australia are initially assessed against each Commonwealth entity’s eligibility criteria, including the requirement for a joint application to be submitted to NHMRC and Cancer Australia. Applicants are notified if not eligible.

---

**PdCCRS Applications Initial Assessment**

NHMRC peer reviewers conduct an initial assessment of the grant proposal against the assessment criteria to create a short-list of applications that proceed to full peer review by NHMRC’s Grant Review Panels. PdCCRS grant applications that are not short-listed for full review are considered Not For Further Consideration and applicants are notified of the outcome.

---

**PdCCRS Applications Assessed**

PdCCRS applications that are short-listed after the initial NHMRC peer review are assessed in two stages. The NHMRC Grant Review Panels conduct an assessment of the grant proposal against the NHMRC Grants scheme assessment criteria and conducts a value with money assessment in the first stage of assessment, Cancer Australia’s PdCCRS Grant Review Committees assess applicant responses to PdCCRS Questions as the second stage of assessment.

---

**PdCCRS Final Score**

Scores from the two stages of assessment (NHMRC scores and PdCCRS Questions scores) are individually weighted and combined to arrive at a final score for each PdCCRS application.
Grant decisions are made
Applications are ranked according to the final PdCCRS score and funded in merit order. Applications recommended for funding are approved by Cancer Australia's CEO

Cancer Australia notifies applicants of the outcome

Grant Recipient's Administering Institution enters into a grant agreement with Cancer Australia

Delivery of grant
Grant recipients undertake the grant activity as set out in the schedule to the grant agreement. Cancer Australia manages all grants including those funded or co-funded by its Funding Partners, by working with the grant recipients, monitoring progress and making sure that payments are made

Evaluation of the PdCCRS
Cancer Australia undertakes periodic evaluations of the performance and administration of the PdCCRS to determine strengths and to identify where improvements can be made

1.1 Introduction
These guidelines contain information for Standard Category A Project grants and Early Career Researcher Categories B-D Project grants for the ‘General Cancer’ and ‘Childhood Cancers of Low Survival’ funding streams (see Attachment A that summarises the grant categories and characteristics/attributes). You must read these guidelines before filling out an application. This document sets out:

- the purpose of the grant program/grant opportunity
- the eligibility and assessment criteria
- how grant applications are considered and selected
- how grant recipients are notified and receive grant payments
- how grant recipients will be monitored and evaluated
- responsibilities and expectations in relation to the opportunity.

GrantConnect is the authoritative source of information on this grant opportunity. Any alterations or addenda to these Guidelines will be published on GrantConnect.

2. About the grant program
Cancer Australia was established by the Australian Government in 2006 to benefit all Australians affected by cancer, as well as their families and carers. Cancer Australia works to reduce the impact of cancer and improve the well-being of those diagnosed by ensuring that evidence informs cancer prevention, screening, diagnosis, treatment and supportive care. Cancer Australia works collaboratively and liaises with a wide range of groups, including those affected by cancer, key stakeholders and service providers with an interest in cancer control. The
agency also focuses on populations who experience poorer health outcomes, including Aboriginal and Torres Strait Islander peoples and people living in rural and remote Australia.

The Priority-driven Collaborative Cancer Research Scheme (PdCCRS) was established by Cancer Australia in 2007. The PdCCRS is a Category 1\(^1\) annual competitive national research project grants scheme which funds cancer research in areas of identified priority to help reduce the impact of cancer in the community and improve outcomes for people affected by cancer.

Between 2007 and 2018, Cancer Australia and its Funding Partners have funded 387 research grants totalling $137 million.

The objectives of the program are to:

- fund research in tumour areas that place a high burden of disease on the Australian community;
- fund applied cancer research projects that directly relate to the identified priorities of Cancer Australia and/or its Funding Partners; and
- fund research that can directly improve cancer outcomes by influencing clinical practice, policy and/or care.

The PdCCRS is aligned with the National Health and Medical Research Council (NHMRC) Ideas Grants, and Clinical Trials and Cohort Studies Grants schemes. The NHMRC facilitates registration and initial assessment of grant applications, and endorses grant applications funded through this scheme in recognition of their scientific quality. The review of grant applications by the NHMRC provides the scheme with a transparent, quality, highly-respected and merit-based peer review research grant process.

A hallmark of the PdCCRS is its ability to bring together funders of cancer research in a national and coordinated scheme to maximise cancer research investment in areas of identified priority across Australia. Cancer Australia’s research priorities are informed by review of the national landscape of funding to cancer research projects and programs, and priorities are developed based on identification of gaps and strategic opportunities for funding of cancer research. Each of Cancer Australia’s Funding Partners independently develops their own research priorities.

### 2019 Funding Partners

**Australian Lions Childhood Cancer Research Foundation**

The Australian Lions Childhood Cancer Research Foundation’s (ALCCRF) vision is 100% survival of kids with cancer. ALCCRF believes that every child deserves a chance at a healthy life. The ALCCRF has raised over $10 million dollars for childhood cancer research and has supported many Australian organisations leading the fight against childhood cancer including support of the Lions Kids Cancer Genome Project. ALCCRF provides funding to childhood cancer research that specifically targets high risk kids for improved survival rates.

---

\(^1\) The PdCCRS is listed on the Australian Competitive Grants Register. Higher Education Providers can include funding by the PdCCRS in their applications to the Department of Education for additional infrastructure funding through the Research Support Program (RSP)
Cure Cancer
Over the past 52 years, Cure Cancer has raised $66.2m to support lifesaving research across all cancer types. They have funded over 500 research grants to young researchers with groundbreaking, innovative ideas, many who have gone on to become leaders in cancer research globally.

Cure Cancer aims to reduce the impact of cancer through:
• Supporting research into cancer;
• Identifying outstanding early-career researchers and providing them with a pathway to establishing independence;
• Promoting the prevention or control of cancer; and
• Raising awareness about cancer in the general community.
Their vision is to make this the last generation to die from cancer.

Leukaemia Foundation of Australia
The Leukaemia Foundation of Australia is the only national charity dedicated to helping those with leukaemia, lymphoma, myeloma and related blood disorders survive and then live a better quality of life. It provides free services and support across Australia and is committed to supporting innovations that drive rapid advancements in treatments and improved quality of life for people living with blood cancer. The Leukaemia Foundation’s research agenda is focused on supporting leading investigators to undertake blood cancer research from PhD scholars undertaking basic science, to world leading researchers discovering new diagnostics and novel therapies and enabling Australian patients to access global clinical trials. They are also committed to harnessing the power of bioinformatics and real world data to accelerate advancements in personalised medicine ultimately delivering on their stretch goal of zero lives lost to blood cancer by 2035.

My Room
My Room is a volunteer-led organisation dedicated to raising funds to achieve a cure for childhood cancers. Over the past 25 years, My Room has raised more than $18 million for childhood cancer research, clinical care, family support, and to improve the quality of life for patients. Its core focus is funding childhood cancer clinical research and trials to achieve its goal of a 100% cure rate, as well as providing medical equipment, and family support.

National Breast Cancer Foundation
The National Breast Cancer Foundation (NBCF) is Australia’s leading not-for-profit, 100% community-funded organisation promoting and funding breast cancer research. Since it was established in 1994, The National Breast Cancer Foundation (NBCF) has injected over $140m of funding to more than 450 projects across the spectrum of breast cancer including grants, individual awards and infrastructure support. NBCF is the most significant national funder of breast cancer research after the National Health and Medical Research Council (NHMRC). NBCF has adopted the ambitious goal of working “towards zero deaths from breast cancer by 2030”, and believes that the only way to achieve this goal is through funding world class research that has a high potential to impact breast cancer. In partnership with the Australian community, the National Breast Cancer Foundation is leading the pursuit for new knowledge in the prevention, diagnosis and treatment of breast cancer.
The Kids’ Cancer Project

The Kids’ Cancer Project is a national charity dedicated to funding childhood cancer research. They support bold scientific research that has the greatest chance of clinical success in the improvement of treatments and survival of childhood cancer. Ultimately, finding a cure is about saving children’s lives and ending the heartbreak childhood cancer brings to so many families.

### 2019 PdCCRS Research Priorities

#### General Cancer Research Priorities

<table>
<thead>
<tr>
<th>Cancer Australia (Category A, B, C, D)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cancer Prevention</strong></td>
</tr>
<tr>
<td>Towards identifying individual and population-based primary prevention interventions, which reduce cancer risk by reducing exposure to cancer risks and increasing protective factors, Cancer Australia’s research priorities in prevention research include the following research focus areas:</td>
</tr>
<tr>
<td>- Determinants of personal behaviours, such as physical activity, sun exposure, alcohol and tobacco use, known to affect cancer risk and interventions;</td>
</tr>
<tr>
<td>- Education to specified populations of patients, health care providers, and at-risk groups about cancer risk and prevention and relevant primary prevention interventions with the intent of promoting increased awareness (including the risk of stigma) and behavioural change, including adherence to preventive interventions and risk-appropriate screening;</td>
</tr>
<tr>
<td>- Trials-based studies of chemo-preventive agents; other (non-vaccine) preventive measures such as prophylactic surgery (e.g., mastectomy, oophorectomy, prostatectomy etc.), use of antibiotics, immune modulators/stimulators or other biological agents; and vaccines for prevention.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Cancer Health Services Research</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Towards providing better quality care (including care that is effective, timely and appropriate), more accessible care, more equal distribution of health gains from health services, safer care, and improved efficiency in the provision of health care, Cancer Australia’s research priorities in health services research include the following research focus areas:</td>
</tr>
<tr>
<td>- Development and testing of health service delivery methods;</td>
</tr>
<tr>
<td>- Studies of future cancer care workforce development;</td>
</tr>
<tr>
<td>- Interventions to increase the quality of health care delivery;</td>
</tr>
<tr>
<td>- Impact of organizational, social, and cultural factors on access to care and quality of care, including studies on variations or inequalities in access among racial, ethnic, geographical or socio-economic groups;</td>
</tr>
<tr>
<td>- Studies of providers such as geographical or care-setting variations in outcomes;</td>
</tr>
<tr>
<td>- Effect of reimbursement and/or insurance on cancer control, outcomes, and survivorship support;</td>
</tr>
<tr>
<td>- Health services research, including health policy and practice and development of guidelines/best practice for healthcare delivery across the diagnostic/preventive/treatment spectrum;</td>
</tr>
<tr>
<td>- Analysis of health service provision, including the interaction of primary and secondary care;</td>
</tr>
<tr>
<td>- Analyses of the cost effectiveness of methods used in cancer prevention, detection,</td>
</tr>
</tbody>
</table>
diagnosis, prognosis, treatment, and survivor care/support;
- Ethical, legal or social implications of research/health service delivery (e.g. genetic counselling);
- Research into systemic or operational barriers to trial enrolment.

General research priorities

Cancer Australia’s framework of general research priorities relate to specific areas of cancer research, tumour types and populations with poorer outcomes. In looking to support research in these areas, Cancer Australia encourages research which focuses on emerging issues, innovation and novel approaches.

Translational research

- Translational research involving the testing or application of technologies, markers and therapies in a clinical setting;
- Translational research associated with surveillance of cancer;
- Translational research to improve: patient care, survivorship, supportive and end of life care.

Tumour types

Research addressing cancers of the: lung, colon & rectum, lymphoma, pancreas, brain, oesophagus, mouth & oropharynx, kidney, stomach, bladder, myeloma, bone & connective tissue, skin (not melanoma) and uterus.

Populations with poor and unwarranted variations in cancer outcomes

Cancer research focusing on populations who experience poor and unwarranted variations in cancer outcomes is strongly encouraged, including variations by:
- Aboriginal and Torres Strait Islander status;
- socioeconomic status;
- geographic location.

Cancer Australia: gynaecological cancers (Category A)

Cancer Control, Survivorship & Outcomes research in gynaecological cancer

- Patient Care, Survivorship Issues, or End-of-Life Care including Complementary and Alternative Approaches;
- Health Services, Economic and Health Policy analysis and Surveillance; especially in relation to cervical cancer
- Behaviour, Education and Communication; especially in relation to endometrial cancer

Translational gynaecological cancer research

- Testing or application of technologies, markers and therapies in a clinical setting;
- Surveillance and prevention of cancer.

Populations with poor and unwarranted variations in cancer outcomes

- Gynaecological cancer research focusing on reducing unwarranted variations/improving outcomes for Aboriginal and Torres Strait Islander women is strongly encouraged.

Applications reflecting these priority areas which encompass endometrial cancer research are particularly encouraged
### Cancer Australia: lung cancer (Category A)

**Aetiology:**
- Exogenous and endogenous factors in the origin and cause of smoking and non-smoking related cancers

**Treatment:**
- The discovery, development or clinical applications of systemic therapies or combinations of localized and systemic therapies

**Cancer Control, Survivorship and Outcomes:**
- Patient-Centred Care including reported outcomes, Survivorship Issues, Palliative Care or End-of-Life Care including Complementary and Alternative Approaches
- Health Services, Economic and Health Policy analysis
- Surveillance after treatment
- Behaviour, Education and Communication

#### Translational research (T3):
- Focussed on translation of evidence into clinical practice, patient care, health services, economic and health policy to improve lung cancer outcomes

#### Populations with poor and unwarranted variations in lung cancer outcomes
Lung cancer in populations with unwarranted variations

### Cure Cancer Australia (Category B, C, D)

Cure Cancer wishes to fund innovative, high-achieving, early-career researchers, and will be assessing the applicant's track record and publications (relative to opportunity). Cure Cancer funding may be used for the applicant's own salary, or the salary of a research assistant, and/or research materials for the specified project. Applicants are advised to consider the following research priorities in their applications:

#### Priority One: General Priorities (Categories B and C applicants only):
- Project grants will be awarded in any field of research (including basic laboratory, epidemiology, psychosocial, translational, and clinical) into prevention, detection, treatment or cure of malignant disease;
- Cure Cancer Australia aims to provide 'start-up' funding to support post-doctoral researchers with less than seven years post-doctoral or less than seven years post-MBBS experience at the time of application (see PdCCRS Grant Guidelines for eligibility criteria for each funding category). Long term clinicians with recent (up to 7 years) PhD qualifications are eligible to apply;
- Cure Cancer selects for leadership and innovation as well as scientific excellence, therefore the applicant must nominate themselves as sole Chief Investigator of their project. This assists early-career researchers to advance their research and to increase their competitiveness for funding from other granting agencies in the future. Please note that this funding cannot be used as part of a larger PdCCRS project grant application.

#### Priority Two: Bioinformatics for cancer research (Category D applicants only)
- Project grants will be awarded in any field of bioinformatics*
bioinformatics is defined as the analysis of biological information, using computers and statistical techniques, to accelerate and enhance cancer research including research related to genomes, proteomes, three-dimensional modelling of biomolecules and biologic systems.

- Cure Cancer aims to provide ‘start-up’ funding to support post-doctoral researchers with less than seven years post-doctoral or less than seven years post-MBBS experience at the time of application; Long term clinicians with recent (up to 7 years) PhD qualifications are eligible to apply;
- Cure Cancer selects for leadership and innovation as well as scientific excellence, therefore the applicant must nominate themselves as sole Chief Investigator of their project. This assists early-career researchers to advance their research and to increase their competitiveness for funding from other granting agencies in the future. Please note that this funding cannot be used as part of a larger PdCCRS project grant application.

**Leukaemia Foundation of Australia (Category C)**

Leukaemia Foundation of Australia is committed to supporting innovations that drive rapid advancements in treatments and improved quality of life for people living with blood cancer. This will be achieved through the creation of a blood cancer innovation ecosystem that fosters research and collaboration leading to our goal of zero lives lost to blood cancers.

The Leukaemia Foundation of Australia invites applications geared towards supporting research into amyloidosis or haematological malignancies in the following priority areas:

- Understanding the biology of haematological malignancies
- Accelerating the adoption of personalised medicine
- New diagnostics
- Novel therapies
- Epidemiology and prevention research

**National Breast Cancer Foundation (Category A)**

NBCF funds research across all aspects of breast cancer provided it has the potential to be impactful and to help us achieve our goal of “towards zero deaths from breast cancer by 2030”. However, applications are particularly encouraged in the following priority areas:

1) New/optimised treatments for Triple negative breast cancer, comprising new target discovery, new delivery methods, new drugs, new therapeutic regimes etc.

2) New/optimised treatments for metastatic/locally advanced breast cancer comprising new target discovery, new delivery methods, new drugs, new therapeutic regimes etc.

3) Health services delivery, comprising big data linkage, epidemiological research to address disparities and variances in outcomes, translation of evidence into policy and practice, quality of healthcare etc.

**The Kids’ Cancer Project (Category A, C)**

The Kids’ Cancer Project is seeking to support collaborative research which will have the greatest impact on childhood cancer survival.
The Kids’ Cancer Project defines a child as an individual up to the age of 18 years old.

Priority 1: Adolescents and young adults (AYAs)

The Australian health system defines a child as an individual between 0 and 15 years old. The Kids’ Cancer Project has extended their definition of a child to include 0 to 18 year olds in response to the significant drop in survival rates once a child reaches 16. The Kids’ Cancer Project recognises that Young Adults are an important consideration, which will now be incorporated in future research funding specifications where possible.

Priority 2: Improving survival and treatments

Improving treatments for childhood cancer will have a direct impact on survival rates. The Kids’ Cancer Project will gain an understanding of best practice and emerging technologies spanning all modalities of treatment. The Kids’ Cancer Project will support research that will have a direct impact on survival rates for all childhood cancers with a relative 5 year survival greater than 85%.

Childhood Cancers of Low Survival Research Priorities

Cancer Australia (Category A, B, C, D)

Cancer Australia’s research priorities in childhood cancers of low survival

Towards increasing survival from childhood cancers through a better understanding of the causes of childhood cancers, their improved diagnosis and more effective treatments, Cancer Australia’s research priorities in childhood cancers of low survival address the following cancer types and research focus areas:

Localised and advanced disease for any of the following cancers of low survival in children (0-14 years)*

- Brain and CNS tumour types – astrocytomas, ependymomas and choroid plexus tumours, intracranial/intraspinal embryonal tumours, and other gliomas, such as DIPG;
- Hepatoblastoma;
- Leukaemia type - acute myeloid leukaemia;
- Sarcoma types - Ewing tumours & related bone sarcomas; fibrosarcomas & other fibrous neoplasms, osteosarcomas; and rhabdomyosarcomas;
- Sympathetic nervous system tumour types - neuroblastoma and ganglioneuroblastoma.

Molecular drivers of childhood cancer (Common Scientific Outline categories of Biology and Aetiology)

- alterations in chromosomes, oncogenes and tumour suppressor genes, such as fusion oncoproteins;
- endogenous factors in the origin and cause of cancer, such as genes and/or genetic polymorphisms and hereditary predisposition.

Novel approaches to diagnosis and treatment (Common Scientific Outline categories of Early Detection, Diagnosis, and Prognosis, and Treatment)

Pre-clinical and trials-based collaborative studies, including;

- genomics-based strategies, such as the use of molecular classification in diagnosis, treatment stratification, and identifying of new therapeutic targets to overcome resistance to conventional treatments;
- development of immune-based therapies, such as adoptive cellular therapies, antibody or antibody-conjugated therapies;
- development of molecular target-based therapies, such as the targeting of fusion
oncoproteins.

* 0-14 years of age is the definition of a child used by the Australian Paediatric Cancer Registry and Cancer Research UK, and is consistent with a definition of <15 years of age used by the American Cancer Society.

**Australian Lions Childhood Cancer Research Foundation (Category C)**

Australian Lions Childhood Cancer Research Foundation (ALCCRF) is dedicated to increasing the survival rates of childhood cancer. ALCCRF will fund research investigating high risk, low survival childhood cancers.

Applications with a focus on **brain cancer, neuroblastoma, or sarcoma**, will be considered for funding.

**Leukaemia Foundation of Australia (Category C)**

Leukaemia Foundation of Australia is committed to supporting innovations that drive rapid advancements in treatments and improved quality of life for people living with blood cancer. This will be achieved through the creation of a blood cancer innovation ecosystem that fosters research and collaboration leading to our goal of zero lives lost to blood cancers.

The Leukaemia Foundation of Australia invites applications geared towards supporting paediatric haematological malignancy research in the following priority areas in childhood cancers of low survival:

- Understanding the biology of haematological malignancies
- Accelerating the adoption of personalised medicine
- New diagnostics
- Novel therapies
- Epidemiology and prevention research

**My Room (Category C)**

My Room will fund clinical or translational research focusing on paediatric cancers of all types in children and adolescents up to 18 years.

Projects that investigate clinical applications of treatments or technologies to enhance prevention, diagnosis, and therapies for paediatric cancers will be considered.

**The Kids’ Cancer Project (Category A, C)**

The Kids’ Cancer Project is seeking to support collaborative research which will have the greatest impact on childhood cancer survival.

The Kids’ Cancer Project defines a child as an individual up to the age of 18 years old.

Research will be funded under the following priority:

**Priority 1: Improving survival and treatments**

Improving treatments for childhood cancer will have a direct impact on survival rates. The Kids’ Cancer Project will gain an understanding of best practice and emerging technologies spanning all modalities of treatment. The Kids’ Cancer Project will support research that will have a direct impact on survival rates for all childhood cancers with a relative 5 year survival
Cancer Australia administers the program according to the Commonwealth Grants Rules and Guidelines (CGRGs).2

2.1 About the PdCCRS Project Grant opportunity

The PdCCRS supports funding for two main types of research grants:
- Standard Project Grants (Category A)
- Early Career Researcher Project Grants (Category B, C, & D)

Each type of grant is available in two funding streams which have separate research priorities:
- General Cancer Research Priorities: Cancer Australia and its Funding Partners have dedicated research priorities ranging across the spectrum of cancer control and across different tumour types.
- Childhood Cancers of Low Survival Research Priorities: Cancer Australia and its Funding Partners have dedicated priorities addressing cancers of low survival in children from 0-14 years of age.

Four different project grant opportunities are available in the PdCCRS and separate PdCCRS Questions application forms are available for:
- Standard Project Grants: General Cancer
- Standard Project Grants: Childhood Cancers of Low Survival
- Early Career Researcher Project Grants: General Cancer
- Early Career Researcher Project Grants: Childhood Cancers of Low Survival

2.1.1 About the PdCCRS Standard Project Grant opportunity

The Standard Project Grant (Category A grants) must demonstrate the following attributes:

Priority-driven

Grant applications must directly relate to either the ‘General Cancer’ or the ‘Childhood Cancers of Low Survival’ research priority area/s specified by Cancer Australia and/or its Funding Partners in this document.

Outcome-/ Impact-focused

Applicants must be able to demonstrate how their project has the potential to improve short, medium and long term outcomes in cancer care and/or cancer control in Australia. Applicants must demonstrate how their research will benefit populations with poorer outcomes within the community, such as Aboriginal and Torres Strait Islander peoples, and those living in particular socioeconomic status areas and geographic locations.

Clear pathway to translation

Applicants are required to describe the approaches and methodologies that will be employed to translate findings of the proposed research into clinical practice, policy, and/or further research in order to improve cancer care and/or cancer control. Applicants must also discuss how the proposed collaboration is necessary for the translation of results and identify any additional future collaborations required to ensure translation of the findings obtained from the proposed project.

Involvement of consumer representatives
Grant applications must outline consumer involvement in the project design and ongoing consumer involvement throughout the life of the project, including the specific roles/activities that the consumer representative/s will undertake. Consumer involvement in the project should be substantive, meaningful and bi-directional.

2.1.2 About the PdCCRS Early Career Researcher Project Grant opportunity
The Early Career Researcher Project Grant (Category B, C, D grants) must demonstrate the following attributes:

Priority-driven
Grant applications must directly relate to either the ‘General Cancer’ or the ‘Childhood Cancers of Low Survival’ research priority area/s specified by Cancer Australia and/or its Funding Partners in this document.

Track record relative to opportunity
Applicants must list publications, their role in the publications, their research experience, other relevant experience including teaching, student supervision and academic administrative responsibilities, and academic qualifications and awards.

Career development
Applicants are required to describe their career development objectives for the next five years and how the chosen research environment will assist in the achievement of the objectives.

Relevance to cancer control
Applicants must describe how their proposed research is relevant to cancer control

Involvement of consumer representatives
Grant applications must outline how consumers were consulted about the relevance of the proposed research or the design of the research project, and how consumers will continue to be involved in the research project and its future development.

3. Grant amount and grant period
The provisional funding allocation for the PdCCRS grant opportunity in 2019/20 is $6.8 million. This is supplemented by the funding committed by Cancer Australia’s Funding Partners $2.3 million.

The amount of funding available for each PdCCRS grant and the duration of the funded project period varies depending on the grant category (see below and Attachment A). The amount of funding awarded to successful applicants is based on assessment of the requested budget by NHMRC for value with money, and the value or duration of the budget may be reduced to ensure the research aims and objectives can be achieved while ensuring value with money.

3.1 Grants available

Standard Project Grants - Category A
Grants are available for a duration of one to three years. The budget in any single year may range from $10,000 to approximately $200,000 (GST exclusive) and the total grant value cannot exceed $200,000/year i.e. $600,000 for a three-year grant.

**Early Career Researcher Project Grants – Categories B, C and D**

**Category B**
- Grants are available for one year duration with maximum funding of $100,000 (GST exclusive) to support post-doctoral researchers with less than 3 years post-doctoral experience, or less than 3 years’ experience after graduation from medical school, at the closing date for applications.

**Category C**
- Grants are available for up to two years duration with maximum funding of $200,000 (GST exclusive), with a maximum in any one year of $100,000 (GST exclusive), to support post-doctoral researchers with greater than 3 years and less than 7 years post-doctoral experience, or greater than 3 years and less than 7 years post-doctoral experience after graduation from medical school, at the closing date for applications.

**Category D**
- Grants in the field of bioinformatics research are available for one year duration with maximum funding of $100,000 (GST exclusive), to support post-doctoral researchers with less than 7 years post-doctoral experience, or less than 7 years after graduation from medical school, at the closing date for applications.

### 3.2 Grant period

**Category A**
The maximum grant period is 3 years.

**Category B**
The maximum grant period is 1 year.

**Category C**
The maximum grant period is 2 years.

**Category D**
The maximum grant period is 1 year. Category D grants are for bioinformatics-based projects only.

### 4. Eligibility criteria

The PdCCRS is aligned with the NHMRC Ideas Grants and Clinical Trials and Cohort Studies Grants schemes. PdCCRS applications must be submitted via the joint application process (see section 7 for application details).
PdCCRS applications will only be accepted if an application has been submitted to NHMRC’s Ideas Grants or Clinical Trials and Cohort Studies Grants schemes and a corresponding PdCCRS Questions application form has been submitted to Cancer Australia.

PdCCRS applications will only be accepted from NHMRC-approved Administering Institutions. A list of NHMRC-approved Administering Institutions and NHMRC’s Administering Institution Policy are available on NHMRC’s website.

The PdCCRS adheres to the relevant Ideas Grants guidelines or the Clinical Trials and Cohort Studies Grants guidelines published by NHMRC, unless otherwise stated in this document.

An eligibility ruling may be made by Cancer Australia at any stage following the close of applications, including during the assessment period. Where an eligibility ruling is being considered, Cancer Australia may request further information in order to assess whether the requirement has been met. Administering Institutions will be notified in writing of ineligible applications and are responsible for advising applicants.

Grant offers may be withdrawn and action taken over the life of a grant, if eligibility criteria to accept and/or continue holding a grant are not met.

Cancer Australia staff will not make eligibility rulings prior to an application being submitted.

### 4.1 Submission Deadlines

Minimum data for applications must be entered into NHMRC’s granting system by 5:00pm AEST 10 April 2019 and must adhere to the NHMRC grant submission deadlines of 5:00pm AEST 8 May 2019. Please refer to NHMRC’s grants guidelines available on GrantConnect for further information.

Completed PdCCRS Questions forms must also be submitted directly to Cancer Australia by 5:00pm AEST 15 May 2019.

Only PdCCRS applications meeting the submission deadlines of Cancer Australia and the NHMRC will be considered eligible for funding consideration.

### 4.2 Chief Investigators and number of grant submissions

The Chief Investigator A (CIA) and Administering Institution must ensure that applications meet all eligibility requirements as set out in these guidelines, at the time of submission and for the duration of the assessment process.

An applicant named as the CIA can only submit a maximum of two PdCCRS applications in any one funding round.

Please note that the limits imposed by NHMRC on the number of grant applications submitted by any Chief Investigator (not just CIA) do not apply to a PdCCRS application provided the NHMRC application indicates it is requesting funding only from Cancer Australia and its Funding Partners.

Applications requesting funding from both NHMRC and Cancer Australia will contribute to the NHMRC limits on the number of grant applications that can be submitted in any one funding round.

### 4.3 Multiple applications/grants

There is no limit on the number of PdCCRS grants that can be held currently by any of the Chief Investigators named on the application.

PdCCRS applicants may elect via the NHMRC application form to be also considered for funding by NHMRC and/or Cancer Councils. Following the assessment process Cancer Australia will work with the NHMRC and/or Cancer Councils to identify which agency will fund the application.
PdCCRS applicants may also submit the same research proposal to other organisations for consideration for funding; however, Cancer Australia and its Funding Partners cannot provide a grant if the applicant has received funding from another organisation for the same research project.

4.4 Grant Category Specific Eligibility criteria

Applicants must additionally comply with the following category-specific criteria in order for their grant applications to be considered eligible for funding through the PdCCRS by Cancer Australia and/or its Funding Partners.

4.4.1 Standard Project Grants – Category A

- Applications can be submitted via NHMRC’s Ideas Grants or Clinical Trials and Cohort Studies Grants schemes;
- The Chief Investigator A (CIA) must be the same person identified as CIA on the NHMRC grant application;
- The CI team must be the same as on the NHMRC application;
- The proposed research must align with at least one research priority area specified by Cancer Australia or its Funding Partners. If your research project does not directly align with the selected research priority area/s, Cancer Australia and/or the Funding Partners are under no obligation to consider your project for funding;
- The project budget must not exceed $600,000 for a 3 year project, $400,000 for a 2 year project or $200,000 for a one year project. Additionally, the annual budget in any one year must not exceed $220,000 with the total budget not exceeding the funding limit;
- If the NHMRC research proposal exceeds the funding (annual or total) and/or duration limits imposed by Cancer Australia and its Funding Partners, the CIA must provide a revision to the scope of the research proposal and an amended budget at Item I of the PdCCRS Questions form to accommodate the PdCCRS limitations;
- The PdCCRS Questions form must be complete and the three assessable criteria questions must have a response. A response of not applicable or not relevant or any argument provided to justify why any of the three assessable criteria questions are not relevant will result in the applications being deemed ineligible;

4.4.2 Early Career Researcher Project Grants – Categories B, C and D

- Applications can only be submitted via NHMRC’s Ideas Grants scheme;
- If NHMRC funding is also being requested, the NHMRC grant proposal cannot exceed 3 years;
- The Sole Chief Investigator (CI) on the PdCCRS application must be the same person identified as CIA on the NHMRC grant application;
- The CI must comply with the number of years which have elapsed after they graduated from their PhD or medical degree to be eligible for funding under each category as outlined in the Table below:

<table>
<thead>
<tr>
<th>Eligibility</th>
<th>Category B</th>
<th>Category C</th>
<th>Category D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Years after attaining PhD/MBBS qualification (as of 15 May 2019)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The proposed research must align with at least one research priority area specified by Cancer Australia or its Funding Partners in the relevant Category of funding. If your research project does not directly align with the selected research priority area/s, Cancer Australia and/or the Funding Partners are under no obligation to consider your project for funding;

- The research project cannot exceed 1 year (Category B or Category D) or 2 years (Category C) in duration;
- The project budget must not exceed $100,000 for a 1 year project or $200,000 for a 2 year project. Additionally the annual budget in any one year of a two year project must not exceed $110,000 with the total budget not exceeding $200,000;
- If the NHMRC research proposal exceeds the funding (annual or total) and/or duration limits imposed by Cancer Australia and its Funding Partners, the CIA must provide a revision to the scope of the research proposal and an amended budget at Item J of the PdCCRS Questions form to accommodate the PdCCRS limitations;
- The PdCCRS Questions form must be complete and the three assessable criteria questions must have a response. A response of not applicable or not relevant or any argument provided to justify why any of the four assessable criteria questions are not relevant will result in the applications being deemed ineligible;

4.4.2.1 Eligibility for funding by Cure Cancer

Applicants applying for funding consideration to Cure Cancer only and not to Cancer Australia or any of its other Funding Partners have the following Funding Partner-specific eligibility criteria:

- In any one round of the PdCCRS, only two applications (Category B, Category C or Category D) per applicant can be submitted for funding or co-funding consideration by Cure Cancer. Only one application per candidate will be funded. Should two applications be deemed eligible for funding, the top ranked application will be selected for funding;
- Researchers already holding a Young Investigator Category C (two-year) PdCCRS grant being funded or co-funded by Cure Cancer Australia are ineligible to apply for further funding in the PdCCRS Early Career Researcher category from Cure Cancer in the first year of their two year grant;
- Applicants who are clinicians of long standing but have less than 7 years post-doctoral experience, applying for funding from Cure Cancer only, are eligible to apply for the relevant Category B, C and D grants.

4.5 Who is eligible to apply for a grant?

To be eligible the applicant must:

- Be an appropriately qualified researcher;
- Be an Australian or New Zealand citizen, a permanent resident, or have a valid work visa;
- Be present in Australia for at least 80% of the project period;
- Be affiliated with an NHMRC-approved Administering Institution; and
- Meet all relevant NHMRC eligibility criteria.

4.6 Who is not eligible to apply for a grant?
The applicant is not eligible to apply if:
- An employee of a 2019 PdCCRS Funding Partner;
- Not an Australian or New Zealand citizen, a permanent resident, or do not have a valid work visa;
- Not going to be present in Australia for at least 80% of the project period;
- Not affiliated with an NHMRC-approved Administering Institution;
- In receipt of funds from, the tobacco industry or organizations deemed by Cancer Australia to be associated with the tobacco industry, regardless of whether the funds are received directly, through collaborators or by other means;
- Employed in a research institute or organisation or, in the case of universities, Faculty or School that allows applications or receives funds from the tobacco industry, whatever the use of those funds may be;
- Employed in a University that accepts funds from the tobacco industry for health related research or services, wherever in the University that research may be done or those services supported.

5. What the grant money can be used for
5.1 Eligible grant activities
Each applicant must declare that they will use the funds provided to undertake activities as outlined in the research proposal and not use funds for activities that do not relate directly to the research activity outlined in the grant application without prior approval from Cancer Australia.
Cancer Australia will terminate its support for a research project if the provisions relating to support from the tobacco industry are breached or it believes that the integrity of the research is threatened by influence from tobacco interests.

5.2 Eligible locations
The research must be conducted at an NHMRC-approved Administering Institution in Australia and the CIA must be present in Australia for at least 80% of the funded project period.
The CIA may request funding to support specific grant activities to be undertaken overseas. In doing so, they must clearly demonstrate that the overseas grant activity is critical to the successful completion of the project, and the equipment/resources required for the grant activity are not available in Australia.

5.3 Eligible expenditure
Funding may be used to support personnel engaged in the conduct of the research, direct research costs, and equipment costs necessary to conduct the research however, equipment costs cannot exceed 10% of the total requested budget across the entire funded project period.
Applicants should refer to the NHMRC definition of direct research costs in the relevant Ideas Grant Guidelines or Clinical Trials and Cohort Studies Grant Guidelines.
5.4 What the grant money cannot be used for

Applicants cannot use the grant funding for activities that are not directly related to the proposed research project. Ineligible activities include:

- purchase of land;
- major capital expenditure;
- the covering of retrospective costs;
- costs incurred in the preparation of a grant application or related documentation;
- subsidy of general ongoing administration of an organisation such as electricity, phone and rent;
- major construction/capital works;
- clinical service delivery;
- infrastructure for clinical services;
- travel unless directly related to the research activity.

6. The assessment criteria

A two-phase assessment process is used to ensure that projects funded by the PdCCRS are scientifically sound and align with the identified research priority area/s of Cancer Australia and/or its Funding Partners (see Attachment B and Attachment C).

PdCCRS grant applications will undergo the first phase of assessment via the relevant NHMRC Grant Review Panels (GRP) for Ideas Grants or Clinical Trials and Cohort Studies Grants.

Grant applications that are rated Not For Further Consideration (NFFC) and do not meet a minimum scientific quality following peer review by NHMRC will not enter the Cancer Australia and Funding Partners’ Phase 2 assessment process.

Grant applications submitted through the NHMRC Ideas Grants scheme will be assessed by the GRPs for: Research Quality, Innovation and Creativity, Significance, and Feasibility.

Grant applications submitted through the NHMRC Clinical Trials and Cohort Studies Grants scheme will be assessed by the GRPs for: Research Quality, Significance and Team Quality and Capability.

Further information on the details of the NHMRC assessment criteria can be found in the relevant Ideas Grants or Clinical Trials and Cohort Studies Grants guidelines posted on GrantConnect.

Grant applications entering into the second phase of assessment will have responses to the PdCCRS Questions assessed by Cancer Australia and its Funding Partners Grant Review Committees.

6.1 Standard Project Grants Assessment Criteria

The NHMRC scores will contribute 40% of the final PdCCRS Standard Project grant score regardless of which NHMRC grants scheme is used to submit the application. The contribution of the NHMRC scores to the final PdCCRS score varies according to the NHMRC assessment criteria for each of the relevant grants schemes. Cancer Australia will weight the NHMRC scores as set out in the table below:

<table>
<thead>
<tr>
<th>NHMRC Ideas Grants</th>
<th>Clinical Trials and Cohort Studies Grants</th>
</tr>
</thead>
</table>

PdCCRS Guidelines
PdCCRS Applicants in the Standard Project Grants category are required to respond to three assessable questions using the PdCCRS Questions application form for Standard Project Grants:

**Question 1**

*Outcomes and Impact (25% of final score)*

Applicants must demonstrate this by describing:

- potential direct outcomes of the research proposal and its impact on cancer care and/or cancer control
- how short/medium and long term outcomes will lead to changes in practice/care/policy and improve outcomes for people affected by cancer
- how the project will impact on populations with poorer cancer outcomes within the community

**Question 2**

*Translation of the results generated from this project (20% of final score)*

Applicants must demonstrate this by describing:

- the approaches and methodologies to be employed to translate the findings of the research into practice, policy and/or further research in order to impact on cancer control and/or cancer care
- how the proposed research collaborations outlined for the project will be directly involved in translating the results
- any future collaborations or groups that will required for the translation of results and how these collaborators/groups will be identified and engaged.

**Question 3**

*Involvement of consumer representatives (15% of final score)*

Applicants must demonstrate this by describing:

- consumer involvement in project design
- ongoing consumer involvement through the life of the project

Scores assigned to the responses to the *PdCCRS Questions* together with the scores received by the NHMRC are weighted and combined to provide a single final score. Applications are ranked by this final score and funding is assigned in merit-based rank order until the available budget is expended.
6.2 Early Career Researcher Project Grants Assessment Criteria

The NHMRC scores will contribute 50% of the final PdCCRS Early Career Researcher Project grant score. Cancer Australia will weigh the NHMRC Ideas Grants scores as outlined in the Table below:

<table>
<thead>
<tr>
<th>NHMRC Ideas Grants</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Research Quality</td>
<td>25%</td>
</tr>
<tr>
<td>Innovation and Creativity</td>
<td>5%</td>
</tr>
<tr>
<td>Significance</td>
<td>20%</td>
</tr>
</tbody>
</table>

PdCCRS Applicants in the Early Career Researcher Project Grants category are required to respond to four assessable questions using the PdCCRS Questions application form for Early Career Researcher Project Grants:

Question 1
Track record of the applicant in regard to opportunity (30% of final score)
Applicants must demonstrate this by providing:
- A list of all publications relevant to the proposed project
- Descriptions of the applicant’s role in key publications/patents
- Details of previous research experience relevant to the proposed research
- Details of other relevant experience including clinical training or practice, postgraduate student supervision or other academic administrative responsibilities
- Details of academic qualifications and awards

Question 2
How the research will contribute to the career development of the applicant (10% of final score)
Applicants must demonstrate this through identifying:
- Career development objectives for the next five years and how the proposed project will foster achievement of the objectives
- Collaborations that will be facilitated by the project
- The reasons for choosing the laboratory or research institution for the proposed research project including mentoring arrangements

Question 3
Relevance to Cancer Control (5% of final score)
Applicants must demonstrate this by describing:
- How the proposed research is relevant to cancer control

Question 4
Involvement of consumer representatives (5% of final score)
Applicants must demonstrate this through identifying:
How consumers will contribute to the study or contributed to its design

How consumer involvement will be included usefully in the development of this project

Scores assigned to the responses to the PdCCRS Questions together with the scores received by the NHMRC are weighted and combined to provide a single final score. Applications are ranked by this final score and funding is assigned in merit-based rank order until the available budget is expended.

7. How to apply

7.1 Overview of application process and timing

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 March 2019</td>
<td>Applications open in NHMRC’s granting system applications open to Cancer Australia’s PdCCRS</td>
</tr>
<tr>
<td>15 March 2019</td>
<td>Applications open to Cancer Australia’s PdCCRS</td>
</tr>
<tr>
<td>17:00 AEST</td>
<td>Minimum data due in NHMRC’s granting system</td>
</tr>
<tr>
<td>10 April 2019</td>
<td>Applications close in NHMRC’s granting system</td>
</tr>
<tr>
<td>8 May 2019</td>
<td>Corresponding completed PdCCRS Questions application form due at Cancer Australia (<a href="mailto:grants@canceraustralia.gov.au">grants@canceraustralia.gov.au</a>)</td>
</tr>
<tr>
<td>August - November</td>
<td>Two phase assessment of applications</td>
</tr>
<tr>
<td>December</td>
<td>Notification to successful and unsuccessful applicants</td>
</tr>
<tr>
<td>January</td>
<td>Negotiation and award of grant agreements</td>
</tr>
<tr>
<td>1 February 2020</td>
<td>Earliest date for start of grant activity</td>
</tr>
<tr>
<td>30 June 2020</td>
<td>Latest date for start of grant activity</td>
</tr>
</tbody>
</table>

Applicants applying to the PdCCRS must submit a joint grant application. A full scientific grant proposal must be submitted through NHMRC’s Granting System for either an Ideas Grant or a Clinical Trials and Cohorts Studies Grant. Applicants should first read NHMRC’s Grant Guidelines for either Ideas Grants or Clinical Trials and Cohort Studies Grants (available on GrantConnect). Applicants should choose whichever guide is relevant to the proposed research project.

Applicants applying to the PdCCRS must indicate on the NHMRC application that the application is to be considered for funding by Cancer Australia by ticking the relevant box on the application form. Applicants applying to the PdCCRS must also submit a PdCCRS Questions application form directly to Cancer Australia. Applicants must read and understand these PdCCRS Grant guidelines, PdCCRS Questions forms, the sample grant agreement and the PdCCRS Research Priorities. Please note that in this current 2019 round of the PdCCRS, Cancer Australia and its Funding Partners have developed research priorities for ‘General Cancer’ and for ‘Childhood Cancers of Low Survival’.
Applications to the PdCCRS must be registered on NHMRC’s granting system. **You must select the ‘Cancer Australia and its Funding Partners’ box in order for your application to be considered for funding by Cancer Australia.** Follow the NHMRC guidelines to submit your project proposal and ensure that the minimum amount of data have been entered by 17:00 AEST 8 May 2019.

The application forms for PdCCRS grants (PdCCRS Questions) can be downloaded from GrantConnect. Ensure the correct form relevant to the proposed project is downloaded and completed.

Completed PdCCRS Questions forms must be submitted to Cancer Australia (grants@canceraustralia.gov.au) by 17:00 AEST 15 May 2019.

**Submission of late PdCCRS Questions forms will only be considered under the following circumstances:**

- technical issues beyond the control of the CIA prevented timely submission of the application
- the grants officer at the Administering Institution failed to submit the application on behalf of the CIA, or
- the applicant’s exceptional circumstances prevent them from submitting the application by the due date; requests for exceptional circumstances to be considered for late lodgement of the application must be submitted to Cancer Australia (grants@canceraustralia.gov.au) ahead of the closing date with the details of the circumstances precluding timely submission identified and the date of anticipated lodgement identified.

All requests will be considered on a case-by-case basis.

### 7.2 PdCCRS Application requirements

To apply for a PdCCRS grant you must, in addition to submitting an NHMRC application to the Ideas Grants or Clinical Trials and Cohort Studies Grants schemes, complete and submit to Cancer Australia PdCCRS Questions application form. Submission of the PdCCRS Questions application form and selection of ‘Cancer Australia and its Funding Partners’ within NHMRC’s granting system (Funding Source) identifies that the applicant is submitting the grant application for consideration for funding by Cancer Australia and/or its Funding Partners.

The proposed research must address at least one of the Cancer Australia or its Funding Partners research priorities to be considered eligible. The research priorities for this current 2019 round of the PdCCRS can be downloaded from GrantConnect.

Cancer Australia’s PdCCRS Questions application forms seek information specific to the PdCCRS. The forms can be downloaded from GrantConnect. Please note that in this current 2019 round of the PdCCRS there are four different PdCCRS Questions forms.

**General Cancer Research Priorities**

- PdCCRS Questions Early Career Researcher Project Grants 2019 – General Cancer Research Priorities

**Childhood Cancers of Low Survival Research Priorities**

Responses to PdCCRS Questions will be assessed by Cancer Australia’s PdCCRS Grant Review Committees without reference to the rest of the grant application (including the NHMRC Grant Proposal and the Cancer Council’s Supplementary Questions).

**Responses to the PdCCRS Questions** should therefore be provided in a manner which *can be read without reference* to the NHMRC Grant Proposal and should be able to be read as a standalone document.

PdCCRS Questions application forms must comply with all content and formatting requirements. The NHMRC application ID and CIA surname must be included in the header of the PdCCRS Questions application form.

Incomplete or non-compliant PdCCRS Questions application forms may be assessed as ineligible.

### 7.3 PdCCRS application submission

The **PdCCRS Questions** application form must be submitted to **Cancer Australia** as a separate PDF file from the NHMRC Grant Proposal PDF file.

The file name for submission to Cancer Australia must be:

'\[App ID\]_\_CancerAustralia\_PdCCRSQs\_[CIA Family Name].pdf’ eg

'123456\_CancerAustralia\_PdCCRSQs\_Smith.pdf’

The applicant is responsible for ensuring that the PdCCRS Questions application form is complete and accurate. Giving false or misleading information is a serious offence under the **Criminal Code 1995** and Cancer Australia will investigate any false or misleading information, and may exclude the application from further consideration.

The completed PdCCRS Questions application form must be submitted by the NHMRC-approved Administering Institution’s RAO directly to grants@canceraustralia.gov.au. **Applications submitted directly by the CIA will not be accepted.**

The deadline for receipt of PdCCRS Questions application forms is 17:00 AEST 15 May 2019.

Once submitted to Cancer Australia, the application is considered final and no changes can be made.

If there is an error or information that is missing, Cancer Australia may ask for clarification or additional information from the applicant via the Administering Institution’s RAO that will not change the nature of the application.

The applicant should keep a copy of the application.

Cancer Australia will acknowledge that it has received your application within three working days.

If you need further guidance around the application process contact Cancer Australia at grants@canceraustralia.gov.au

### 7.4 Withdrawal of applications

Applications may be withdrawn from consideration for funding under the PdCCRS at any time by written notice from the Administering Institution’s RAO to Cancer Australia at grants@canceraustralia.gov.au
7.5 Questions during the application process
If you have any questions during the application period, contact grants@canceraustralia.gov.au
Responses to emailed questions will be provided within two working days.

8. The grant selection process

8.1 Assessment of grant applications
PdCCRS Questions forms are initially reviewed against the eligibility criteria. Only eligible applications with a corresponding NHMRC grant application will move to the two phase assessment process outlined in section 6. Applicants who have submitted an application assessed as ineligible will be notified in writing by Cancer Australia within one month of the application submission date.

Applications to the PdCCRS are assessed in two stages and scores provided from each stage of the assessment contribute to the final PdCCRS score (see Attachments B and C).

In the first phase of assessment, eligible PdCCRS applications will be assessed and ranked via the NHMRC Ideas Grants or Clinical Trials and Cohort Studies Grants assessment processes (see the relevant guidelines available from GrantConnect). Following initial assessment by NHMRC peer reviewers, the least competitive applications will be removed from further consideration (NFFC; Not For Further Consideration). Cancer Australia will notify PdCCRS applicants who are assessed as NFFC in writing following notification from NHMRC.

The remaining applications are then assessed against the assessment criteria for the relevant grants scheme by NHMRC peer review panels. Scores from the NHMRC grant review process for all applications to the PdCCRS are provided to Cancer Australia.

NHMRC peer review panels also conduct a value with money assessment for each application and may make recommendations about the amount of funding to be offered if the application is ranked sufficiently high to be fundable.

PdCCRS grant applications that are rated NFFC by the NHMRC and do not meet a minimum scientific quality following peer review by NHMRC grant review panels will not enter the Cancer Australia and Funding Partners’ Phase 2 assessment process.

In the second phase of assessment, Cancer Australia’s PdCCRS Grant Review Committees assess applicant responses to the PdCCRS Questions using the PdCCRS assessment criteria (see section 6).

The alignment of research projects to the research priority area/s of Cancer Australia and/or its Funding Partners will also be assessed; however, this assessment will not contribute to the final score.

The scores assigned to the PdCCRS Questions assessment criteria together with the scores received by the NHMRC are weighted and combined to provide a single final score (see section 6 and Attachments B and C). All applications are ranked according to this final score and funding is assigned in rank order until the available budgets for Cancer Australia and/or its Funding Partners are expended.

8.2 Who will assess applications?
NHMRC will conduct peer review for the funding round in accordance with the NHMRC’s Principles of Peer Review, available from NHMRC’s website.
Cancer Australia’s Grant Review Committees comprise representatives nominated by Cancer Australia and its Funding Partners and includes consumer representation. Contemporary research suggests while researchers are best placed to assess the quality and feasibility of research, judgements on the broader significance of the research and impacts on society, benefit greatly from an assessment by consumers\textsuperscript{3}.

Seeking consumer input at all stages of research from conception through to dissemination and implementation of study findings across the research spectrum is an important element of the assessment criteria.

8.3 Who will approve grants?
The CEO Cancer Australia will approve the recommendations for funding or co-funding to be offered by Cancer Australia. The CEOs of each of the Funding Partners or their nominated representative will approve the funding or co-funding contribution recommendations made by the Manager, Research & Clinical Trials, Cancer Australia.

9. Notification of application outcomes
Once final funding approvals have been received, Cancer Australia will advise all applicants of the outcome of their application by email on the same day in December.

A formal letter of offer will be sent to successful applicants and will contain details of any specific conditions attached to the funding. The successful applicants will be provided with a timeframe in which to accept or decline the offer of funding.

9.1 Feedback on your application
Unsuccessful applicants will be provided the opportunity to seek feedback on the strengths and weaknesses of their responses to the PdCCRS Questions. Feedback teleconferences will be arranged in January to February to assist applicants in addressing any weaknesses should they wish to re-submit their application in March for consideration for funding in the next PdCCRS funding round.

10. Successful grant applications

10.1 The grant agreement
Administering Institutions responsible for administering successful applications must enter into a legally binding grant agreement with the Commonwealth represented by Cancer Australia. Cancer Australia uses the standard grant agreement and a sample agreement can be downloaded from GrantConnect.

\textsuperscript{3} Saunders C, Girgis A, Butow P, Crossing S, Penman A: Operationalising a model framework for consumer and community participation in health and medical research (http://www.anzhealthpolicy.com/content/4/1/13 ) accessed 10 July 2013
Administering Institutions must indicate their willingness to comply with the terms and conditions outlined in the PdCCRS grant agreement on the PdCCRS Questions application form prior to submission of the application.

Each agreement has general terms and conditions that cannot be changed. Cancer Australia uses a schedule to outline the specific grant requirements.

Cancer Australia must execute a grant agreement with you before any payments can be made. Cancer Australia is not responsible for any expenditure until a grant agreement is executed. If the grant recipient chooses to start the project before the grant agreement has been executed, they do so at their own risk.

The Commonwealth may recover grant funds if there is a breach of the grant agreement.

10.2 Information required from grant recipients

Grant recipients will be required to provide additional information about their research activity, key milestones and proposed commencement date before a grant agreement can be executed. Grant recipients will be provided with a draft Schedule to the grant agreement for completion shortly after receiving the formal letter of offer.

10.3 Specific legislation, policies and industry standards

Where relevant, particularly for ethics and biosafety, Cancer Australia and its Funding Partners funded research must have received approval from the relevant institutional committees and approval bodies before research activities can commence.

10.4 How we pay the grant

The grant agreement will state:
- maximum grant amount to be paid
- the financial contributions made by Cancer Australia and/or the Funding Partner(s)
- schedule of payments to be made throughout the project period

Cancer Australia will not exceed the maximum grant amount under any circumstances. Extra costs must be met by funding sources other than Cancer Australia and its Funding Partners.

Cancer Australia and/or the Funding Partner(s) will make payments according to the agreed schedule set out in the grant agreement. Payments are made subject to satisfactory progress on the planned research activities.

10.5 Grants Payments and GST

10.5.1 Taxation

Applicants are advised to carefully consider the likely taxation treatment of any funding provided by the Commonwealth prior to submitting an application. For some general guidance on the taxation treatment of Grants and funding from the Commonwealth, applicants may wish to refer to the Australian Tax Office website at www.ato.gov.au. Applicants are advised to seek independent advice on this issue from a taxation professional.
10.5.2  Goods and Services Tax (GST)
Due to changes to the A New Tax System (Goods and Services Tax) Act 1999 (GST Act) from 1 July 2012, a payment from Cancer Australia will not be subject to GST if all of the following apply:

- the payment is made by a government related entity (GRE) to another government related entity for making a supply;
- the payment is covered by an appropriation under an Australian law or is made under a specified intergovernmental health reform agreement;
- the payment satisfies the non-commercial test.

As a consequence of these amendments to the GST Act, GST will no longer be included in instances where all of the above requirements are satisfied.

11.  Announcement of grants
Cancer Australia funded or co-funded grants will be listed on the GrantConnect website 21 calendar days after the date of effect as required by Section 5.3 of the CGRGs.

All successful PdCCRS grant applications will be announced on Cancer Australia’s website.

12.  How Cancer Australia monitors grant activity

12.1  Variations
A variation is a change (including a delay) to a grant or to grant progress. There are limited circumstances where it is appropriate to vary a PdCCRS grant relative to the originally submitted grant proposal. Grant recipients will be provided a ‘New Starter Guide’ with the formal letter of offer which details the circumstances under which a variation can be requested and details of how to submit a request for variation to Cancer Australia.

Grant recipients should not assume that a variation request will be successful. Cancer Australia will consider requests based on provisions in the grant agreement and the likely impact on achieving planned outcomes.

12.2  Reporting
Grant recipients must submit reports as outlined in the Schedule to the grant agreement. Cancer Australia will remind recipients of reporting obligations before a report is due. Cancer Australia expects recipients to report on:

- progress against agreed milestones and outcomes, and
- expenditure of the grant.

Cancer Australia will monitor progress and expenditure by assessing the submitted reports. Occasionally Cancer Australia may seek further information to assist the review of the submitted reports.

All information provided to Cancer Australia in reports may be used for internal reporting and reporting to government. This information may also be used by Cancer Australia when reviewing or evaluating funded research projects, funding schemes, or designing future schemes.
12.2.1 **Annual Financial Reports**
Annual financial reports are required in a form prescribed by Cancer Australia. Annual financial statements must be submitted by email directly to Cancer Australia’s Contact Officer by the report due date as outlined in the Schedule to the grant agreement.

At the completion of a grant (3 months after the project end date) or upon transfer to a new Administering Institution, an audited financial acquittal is required to be submitted by email to Cancer Australia’s Contact Officer.

A template will be provided by Cancer Australia to assist recipients with their reporting obligations.

12.2.2 **Annual Progress reports**
Annual Progress reports are required in a form prescribed by Cancer Australia. A template will be provided by Cancer Australia to assist recipients with their reporting obligations. Progress reports will include (but not be limited to):

- Project information: Date of report, project ID, project title
- Project during current reporting period including progress against planned activities, changes to Chief and Associate Investigators, project progress (outlining research progress against planned activities, any departures from the original timeline or challenges or barriers to progress, and plans for overcoming setbacks), involvement of consumers in the research, publications arising as a direct result of the funding provided, and whether the research has influenced clinical practice or policy.

Progress Reports must be submitted by email directly to Cancer Australia’s Contact Officer by the report due date as outlined in the Schedule to the grant agreement.

Cancer Australia and/or the Funding Partner will only make grant payments when the Annual Progress Report has been reviewed and accepted.

Recipients must discuss any reporting delays with Cancer Australia as soon as apparent.

12.2.3 **Ad-hoc reports**
Cancer Australia may ask you for ad-hoc reports from grant recipients. This may be to provide an update on progress, or any significant delays or difficulties in completing the project.

12.2.4 **Final report**
A Final Report is required in a form prescribed by Cancer Australia and must be submitted within 3 months of the end of the project period. A template will be provided by Cancer Australia to assist recipients with their reporting obligations.

The Final Report will include (but not be limited to):

- Project information: project ID, project title, how research addressed the research priorities of Cancer Australia and/or its Funding Partners
- Details of Investigators and Collaborators
- Project over duration of funding including: achievements against planned aims, significant research findings/outcomes, impact/potential impact of research findings, how the findings will be translated into further research/clinical practice/policy, and consumer involvement in the planning, execution and dissemination of outcomes
- Academic output arising as a direct result of the funded research
Where a Grant recipient fails to submit a satisfactory report, Cancer Australia may determine that funds have not been used in accordance with conditions applicable to the Grant as stipulated in Clauses 10 and 11 of the Standard Grant Agreement. In this situation, Cancer Australia may:

- request that all or part of the Grant be repaid, or
- withhold further payments until satisfactory progress can be demonstrated, or
- require the project period of the grant to be extended by Variation to allow completion of activities against planned aims. Please note that in this situation, no further funds will be available from Cancer Australia and/or its Funding Partners.

### 12.2.5 Audited financial acquittal report

At the completion of a grant (3 months after the project end date) or upon transfer to a new Administering Institution, an audited financial acquittal is required to be submitted by email to Cancer Australia’s Contact Officer. A template will be provided by Cancer Australia to assist recipients with their reporting obligations.

A Cancer Australia approved auditor is a person who is registered as a company auditor under the Corporations Act 2001 (Cth) or, an appropriately qualified member of the Institute of Chartered Accountants in Australia, the Institute of Public Accountants or of CPA Australia and may be a staff member from your Administering Institution, such as an accountant or financial officer providing they have had no direct role in the research project.

Cancer Australia will ask for a certification that all funds expended were used in accordance with the purposes for which the funds were provided and the Administering Institution has complied with the terms and conditions of the Agreement.

### 12.3 Compliance visits

Cancer Australia may visit grant recipients during or at the completion of grant activity to review compliance with the grant agreement. Cancer Australia will provide reasonable notice of any compliance visit.

### 12.4 Evaluation

Cancer Australia undertakes periodic evaluations of the PdCCRS grant program to assess whether the outcomes and objectives have been achieved and to identify where improvements can be made. Cancer Australia may use information from your application and reports for this purpose. Cancer Australia may also interview recipients, or ask for more information to help Cancer Australia understand how the grant impacted the recipients and to evaluate how effective the program was in achieving its outcomes.

Cancer Australia may contact you up to five years after you finish your grant for more information, such as additional publications arising from the research or clinical practice or policy changes that may have resulted from the research, to assist with this evaluation.

### 12.5 Acknowledgement

The Administering Institution must ensure that the funding from Cancer Australia and Funding Partners (if any), for a PdCCRS research project is properly acknowledged in any correspondence, public announcement, advertising material, research report or other material produced by, on behalf of or through the Administering Institution or a Participating Institution that relates to the research project.
The correct form of acknowledgment is outlined in the grant agreement and must acknowledge the PdCCRS, the grant number, Cancer Australia and Funding Partners where relevant.

The Administering Institution must ensure that the Cancer Australia and Funding Partners (if any) logo is not used without Cancer Australia and Funding Partners (if any) prior written consent to that specific use of the logo, which Cancer Australia and Funding Partners (if any) may give, refuse or revoke in its absolute discretion. Cancer Australia may give consent subject to any terms or conditions that it considers reasonable.

13. **Probity**

The Australian Government will make sure that the grant opportunity process is fair, according to the published guidelines, incorporates appropriate safeguards against fraud, unlawful activities and other inappropriate conduct and is consistent with the CGRGs.

These guidelines may be changed from time-to-time by Cancer Australia. When this happens, the revised guidelines will be published on [GrantConnect](https://grantconnect.canceraustralia.gov.au).

**13.1 Enquiries and feedback**

Should an applicant wish to lodge a dispute or complaint about the application and assessment process, they should do so in writing to the Cancer Australia at: grants@canceraustralia.gov.au. Disputes and complaints must be lodged within 28 days of the Chief Investigator A receiving notification of the application outcome. The complainant should provide details of the basis upon which the dispute or complaint is being lodged, including:

- a clear statement as to what the complainant considers was defective in the funding process
- copies of, or references to, evidence supporting the complaint, and
- a statement as to what the complainant wishes to achieve from the complaint process

Receipt of the complaint will be acknowledged in writing within 5 working days of receiving the complaint. If further correspondence or information is required, the complainant will be given no less than 15 working days to respond to any communication from Cancer Australia.

Further information is provided in the [Cancer Australia Procurement and Grants Complaint Handling Policy (DOC 47.5KB)](https://grantconnect.canceraustralia.gov.au/files/22072015050825478_Cancer-Australia-Procurement-and-Grants-Complaint-Handling-Policy.pdf)

If you do not agree with the way Cancer Australia has handled your complaint, you may complain to the Commonwealth Ombudsman. The Ombudsman will not usually look into a complaint unless the matter has first been raised directly with Cancer Australia.

The Commonwealth Ombudsman can be contacted on:

- **Phone (Toll free):** 1300 362 072
- **Email:** ombudsman@ombudsman.gov.au
- **Website:** www.ombudsman.gov.au

**13.2 Conflicts of interest**

Any conflicts of interest could affect the performance of the grant opportunity or program. These may be a conflict of interest, or perceived conflict of interest, if Cancer Australia’s staff, any member of a committee or advisor and/or any applicant or their personnel:
- has a professional, commercial or personal relationship with a party who is able to influence the application selection process, such as an Australian Government officer, or member of a grant review committee
- has a relationship with or interest in, an organisation, which is likely to interfere with or restrict the applicants from carrying out the proposed activities fairly and independently or
- has a relationship with, or interest in, an organisation from which they will receive personal gain because the organisation receives a grant under the grant program/grant opportunity.

Applicants will be asked to declare, as part of the application, any perceived or existing conflicts of interests or that, to the best of their knowledge, there is no conflict of interest.

If an applicant later identifies an actual, apparent, or perceived conflict of interest, it is the applicant’s responsibility to inform Cancer Australia in writing immediately.

Conflicts of interest for Australian Government staff will be handled as set out in the Australian Public Service Code of Conduct (Section 13(7)) of the Public Service Act 1999. Committee members and other officials including the decision maker must also declare any conflicts of interest.

### 13.3 Privacy

Cancer Australia treats applicants’ personal information according to Privacy Act 1988 and the Australian Privacy Principles. This includes letting applicants know:

- what personal information is collected
- why personal information is collected
- who we give personal information to.

Personal information can only be disclosed to someone else for the primary purpose for which it was collected, unless an exemption applies.

The Australian Government may also use and disclose information about grant applicants and grant recipients under this grant opportunity in any other Australian Government business or function. This includes giving information to the Australian Taxation Office for compliance purposes.

Cancer Australia may share information provided to it by applicants with other Commonwealth entities for purposes including government administration, research or service delivery, according to Australian laws.

Applicants are required as part of their application to declare their ability to comply with the Privacy Act 1988, including the Australian Privacy Principles, and impose the same privacy obligations on any employees or subcontractors engaged by the applicant to assist with the activity, in respect of personal information collected, used, stored, or disclosed in connection with the activity.

Accordingly, applicants must not do anything, which if done by Cancer Australia would breach an Australian Privacy Principle as defined in the Act.

### 13.4 Confidential information

Other than information available in the public domain, applicants agree not to disclose to any person, other than Cancer Australia, any confidential information relating to the grant application and/or agreement, without Cancer Australia’s prior written approval. The obligation will not be breached where the applicant is required by law, Parliament or a stock exchange to disclose the relevant information or where the relevant information is publicly available (other than through breach of a confidentiality or non-disclosure obligation).
Cancer Australia may at any time, require applicants to arrange for the applicant or their employees, agents or subcontractors to give a written undertaking relating to nondisclosure of Cancer Australia’s confidential information in a form considered acceptable by Cancer Australia.

Cancer Australia will keep any information in connection with the grant agreement confidential to the extent that it meets all of the three conditions below:

1. you clearly identify the information as confidential and explain why we should treat it as confidential
2. the information is commercially sensitive
3. revealing the information would cause unreasonable harm to you or someone else.

Cancer Australia will not be in breach of any confidentiality agreement if the information is disclosed to:

- the [committee] and other Commonwealth employees and contractors to help Cancer Australia manage the program effectively
- employees and contractors of Cancer Australia’s Knowledge Management department to research, assess, monitor and analyse Cancer Australia’s programs and activities
- employees and contractors of other Commonwealth agencies for any purposes, including government administration, research or service delivery
- other Commonwealth, State, Territory or local government agencies in program reports and consultations
- the Auditor-General, Ombudsman or Privacy Commissioner
- the responsible Minister or Parliamentary Secretary, and
- a House or a Committee of the Australian Parliament.

The grant agreement may also include any specific requirements about special categories of information collected, created or held under the grant agreement.

### 13.5 Freedom of information

All documents in the possession of the Australian Government, including those about this grant opportunity, are subject to the [Freedom of Information Act 1982](https://www.legislation.gov.au) (FOI Act).

The purpose of the FOI Act is to give members of the public rights of access to information held by the Australian Government and its entities. Under the FOI Act, members of the public can seek access to documents held by the Australian Government. This right of access is limited only by the exceptions and exemptions necessary to protect essential public interests and private and business affairs of persons in respect of whom the information relates.

All Freedom of Information requests must be referred to the Freedom of Information Coordinator in writing.

By mail: Elmer Wiegold  
Freedom of Information Coordinator  
Locked Bag 3  
Strawberry Hills  
NSW 2012

By email: elmer.wiegold@canceraustralia.gov.au
14. Cancer Australia policies
Administering Institutions and CIAs are bound by the conditions of the Funding Agreement. It is the responsibility of Administering Institutions and CIs to be aware of, and be compliant with, all relevant legislation and policies relating to the conduct of the Research Activity.
Cancer Australia and its Funding Partners funded research must be conducted in accordance with the Australian Code for the Responsible Conduct of Research 2018.
For further information on the expectations of Administering Institutions and CIs, see NHMRC’s website.

15. Glossary

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>assessment criteria</td>
<td>are the specified principles or standards, against which applications will be judged. These criteria are also used to assess the merits of proposals and, in the case of a competitive grant opportunity, to determine application rankings.</td>
</tr>
<tr>
<td>commencement date</td>
<td>the expected start date for the grant activity</td>
</tr>
<tr>
<td>date of effect</td>
<td>can be the date on which a grant agreement is signed or a specified starting date. Where there is no grant agreement, entities must publish information on individual grants as soon as practicable.</td>
</tr>
<tr>
<td>decision maker</td>
<td>the person who makes a decision to award a grant</td>
</tr>
<tr>
<td>eligibility criteria</td>
<td>refers to the mandatory criteria which must be met to qualify for a grant. Assessment criteria may apply in addition to eligibility criteria.</td>
</tr>
<tr>
<td>Commonwealth entity</td>
<td>a Department of State, or a Parliamentary Department, or a listed entity or a body corporate established by a law of the Commonwealth. See subsections 10(1) and (2) of the PGPA Act</td>
</tr>
<tr>
<td>Commonwealth Grants Rules and Guidelines (CGRGs)</td>
<td>Establish the overarching Commonwealth grants policy framework and articulate the expectations for all non-corporate Commonwealth entities in relation to grants administration. Under this overarching framework, non-corporate Commonwealth entities undertake grants administration based on the mandatory requirements and key principles of grants administration.</td>
</tr>
<tr>
<td>Term</td>
<td>Definition</td>
</tr>
<tr>
<td>------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| grant                        | for the purposes of the CGRGs, a ‘grant’ is an arrangement for the provision of financial assistance by the Commonwealth or on behalf of the Commonwealth:  
  a. under which relevant money\(^4\) or other CRF money\(^5\) is to be paid to a grant recipient other than the Commonwealth; and  
  b. which is intended to help address one or more of the Australian Government’s policy outcomes while assisting the grant recipient achieve its objectives. |
| grant activity/activities     | refers to the project/tasks/services that the grant recipient is required to undertake                                                   |
| grant agreement               | sets out the relationship between the parties to the agreement, and specifies the details of the grant                                      |
| GrantConnect                  | is the Australian Government's whole-of-government grants information system, which centralises the publication and reporting of Commonwealth grants in accordance with the CGRGs |
| grant opportunity             | refers to the specific grant round or process where a Commonwealth grant is made available to potential grantees. Grant opportunities may be open or targeted, and will reflect the relevant grant selection process. |
| grant program                 | a ‘program’ carries its natural meaning and is intended to cover a potentially wide range of related activities aimed at achieving government policy outcomes. A grant program is a group of one or more grant opportunities under a single [entity] Portfolio Budget Statement Program. |
| grant recipient               | the individual/organisation which has been selected to receive a grant                                                                     |
| NHMRC                        | National Health and Medical Research Council                                                                                           |
| NHMRC Granting System        | NHMRC’s electronic grants management solution for grant application, assessment and administration.                                       |

---

\(^4\) Relevant money is defined in the PGPA Act. See section 8, Dictionary.

\(^5\) Other CRF money is defined in the PGPA Act. See section 105, Rules in relation to other CRF money.
<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS Program</td>
<td>described within the entity’s Portfolio Budget Statement, PBS programs each link to a single outcome and provide transparency for funding decisions. These high-level PBS programs often comprise a number of lower level, more publicly recognised programs, some of which will be Grant Programs. A PBS Program may have more than one Grant Program associated with it, and each of these may have one or more grant opportunities.</td>
</tr>
<tr>
<td>PdCCRS</td>
<td>Cancer Australia’s Priority-driven Collaborative Cancer Research Scheme.</td>
</tr>
<tr>
<td>schedule</td>
<td>the project-specific activities and milestones that form part of the Funding Agreement.</td>
</tr>
<tr>
<td>selection process</td>
<td>the method used to select potential grantees. This process may involve comparative assessment of applications or the assessment of applications against the eligibility criteria and/or the assessment criteria.</td>
</tr>
</tbody>
</table>
| value with money      | value with money in this document refers to ‘value with relevant money’ which is a judgement based on the grant proposal representing an efficient, effective, economical and ethical use of public resources and determined from a variety of considerations. When administering a grant opportunity, an official should consider the relevant financial and non-financial costs and benefits of each proposal including, but not limited to:  
  ▪ the quality of the project proposal and activities;  
  ▪ fitness for purpose of the proposal in contributing to government objectives;  
  ▪ that the absence of a grant is likely to prevent the grant recipient and government’s outcomes being achieved; and  
  ▪ the potential grant recipient’s relevant experience and performance history. |
16. **Attachment A  PdCCRS Grant Characteristics/Attributes**

### Standard Project Grant
**Category A**

<table>
<thead>
<tr>
<th>Grants</th>
<th>Category A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration</td>
<td>1 to 3 years</td>
</tr>
<tr>
<td>Field</td>
<td>All</td>
</tr>
<tr>
<td>Eligibility</td>
<td>Any year post-PhD/ post-MBBS</td>
</tr>
<tr>
<td>Grant amount (GST-excl)</td>
<td>Cannot exceed:</td>
</tr>
<tr>
<td></td>
<td>• $0.1m - $0.2m/annum</td>
</tr>
<tr>
<td></td>
<td>• $0.2m/annum ± 10% in any year</td>
</tr>
<tr>
<td></td>
<td>• $0.6m total</td>
</tr>
</tbody>
</table>

**Attributes:**
1. Priority Driven
2. Outcome- / Impact-focussed
3. Clear pathway to translation
4. Involvement of consumer representatives

### Early Career Researcher Project Grant
**Category B**

<table>
<thead>
<tr>
<th>Grants</th>
<th>Category B</th>
<th>Category C</th>
<th>Category D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration</td>
<td>1 year</td>
<td>Up to 2 years</td>
<td>1 year</td>
</tr>
<tr>
<td>Field</td>
<td>All</td>
<td>All</td>
<td>Bioinformatics only</td>
</tr>
<tr>
<td>Eligibility</td>
<td>&lt;3 yrs post-PhD/ post-MBBS</td>
<td>&gt;3 yrs and &lt; 7 yrs post-PhD/ post-MBBS</td>
<td>&lt;7 yrs post-PhD/ post-MBBS</td>
</tr>
<tr>
<td>Grant amount (GST-excl)</td>
<td>Cannot exceed:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• $0.1m total</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cannot exceed:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• $0.1m/annum (± 10% for 2 yr grants)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• $0.2m total for 2 yr grants</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cannot exceed:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• $0.1m total</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Attributes:**
1. Priority Driven
2. Track record relative to opportunity
3. Career Development
4. Relevance to Cancer control
5. Involvement of consumer representatives
17. Attachment B  PdCCRS Assessment Process Map – Standard Project Grants (Category A)

**NHMRC**

- Application to NHMRC*
- Ideas Grants
- Clinical Trials and Cohort Studies Grants

**Joint application process**

- Eligible
- Applications that meet both eligibility criteria
- 40% PdCCRS FINAL Score
  - Ideas Grants
  - Clinical Trials and Cohort Studies

**PdCCRS Phase Two Assessment**

- Cancer Australia’s PdCCRS Grant Review Committees (GRCs)

**Cancer Australia**

- PdCCRS Questions Application Form
- Eligible
- 60% PdCCRS FINAL Score

**Unsuccessful**

- i. Rated Not For Further Consideration
- OR
- ii. GRP Score lower than defined threshold
- OR
- iii. Research Quality Score lower than defined threshold

**PdCCRS Assessment Process Map**

- Standard Project Grants (Category A)

**PdCCRS Questions**

<table>
<thead>
<tr>
<th>Weighting</th>
<th>PdCCRS Criterion</th>
</tr>
</thead>
<tbody>
<tr>
<td>25%</td>
<td>Outcomes &amp; Impact</td>
</tr>
<tr>
<td>25%</td>
<td>Translation of Results</td>
</tr>
<tr>
<td>10%</td>
<td>Involvement of Consumer Representatives</td>
</tr>
</tbody>
</table>

*Selecting the box for consideration for funding by Cancer Australia*

**NHMRC**

- Application to NHMRC* Ideas Grants
  - Eligible
  - Applications that meet both eligibility criteria

**Joint application process**

**PdCCRS Questions Application Form**

**Cancer Australia**

**PdCCRS Phase Two Assessment**

- Cancer Australia’s PdCCRS Grant Review Committees (GRCs)
  - 50% PdCCRS FINAL Score

**PdCCRS Phase One Assessment**

- NHMRC Grant Review Panels (GRPs)
  - Ideas Grants
    - Initial Assessment and full GRP scoring against assessment criteria for each NHMRC grant program

**50% PdCCRS FINAL Score**

### Ideas Grants

<table>
<thead>
<tr>
<th>PdCCRS Weighting</th>
<th>NHMRC Criterion</th>
</tr>
</thead>
<tbody>
<tr>
<td>25%</td>
<td>Research Quality</td>
</tr>
<tr>
<td>5%</td>
<td>Innovation &amp; Creativity</td>
</tr>
<tr>
<td>20%</td>
<td>Significance</td>
</tr>
</tbody>
</table>

**Unsuccessful**

- i. Rated Not For Further Consideration
  - OR
  - ii. GRP Score lower than defined threshold
  - OR
  - iii. Research Quality Score lower than defined threshold

**PdCCRS Questions**

<table>
<thead>
<tr>
<th>Weighting</th>
<th>PdCCRS Criterion</th>
</tr>
</thead>
<tbody>
<tr>
<td>30%</td>
<td>Track Record of Applicant</td>
</tr>
<tr>
<td>10%</td>
<td>Research Contribution to Career Development</td>
</tr>
<tr>
<td>5%</td>
<td>Relevance to Cancer Control</td>
</tr>
<tr>
<td>5%</td>
<td>Involvement of Consumer Representatives</td>
</tr>
</tbody>
</table>

*Selecting the box for consideration for funding by Cancer Australia